Lv71
5000 积分 2021-03-16 加入
A TME-Responsive Oxygen-Self-Supplying Hybridized Polymersome for Synergistic Triple-Modal Therapy and Precision Theranostics in Hypoxic Tumors
1个月前
已完结
Urease‐Mediated Reversible Calcium Carbonate Mineralization for Single Living Yeast Cell Nanoencapsulation
1个月前
已完结
Hierarchical MXene/Enzyme@Covalent Organic Framework Composite by Template Method for Photothermal‐Enhanced Lipase Catalysis
1个月前
已完结
Molecular mechanisms of antibiotic resistance revisited
2个月前
已完结
Understanding and overcoming multidrug resistance in cancer
2个月前
已完结
Nanomedicine therapeutic approaches to overcome cancer drug resistance
2个月前
已完结
Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges
2个月前
已完结
Enzyme miniaturization: Revolutionizing future biocatalysts
4个月前
已完结
Protein Dynamics, Thermal Stability, and Free-Energy Landscapes: A Molecular Dynamics Investigation
6个月前
已完结
The catalytic pathway of horseradish peroxidase at high resolution
7个月前
已完结
Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate
1年前
已采纳
Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91
1年前
已采纳
Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274-82
1年前
已采纳
Reply to Jas Singh's Letter to the Editor re: Marc Sbizzera, Nicolas Morel-Journel, Alain Ruffion, et al. Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition. Eur Urol. 2022;81:305-12
1年前
已采纳
Re: Changes in Prostate-specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
1年前
已采纳
Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts Published in European Urology
1年前
已采纳
Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia's Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80
1年前
已采纳
Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015
1年前
已采纳
Re: Percentage Gleason Pattern 4 and PI-RADS Score Predict Upgrading in Biopsy Grade Group 2 Prostate Cancer Patients Without Cribriform Pattern
1年前
已采纳
A Transgender Patient with Prostate Cancer: Lessons Learnt
1年前
已采纳
皖公网安备34019202002308
